End of the line for cannabinoid receptor 1 as an anti-obesity target?

Nat Rev Drug Discov. 2008 Dec;7(12):961-2. doi: 10.1038/nrd2775.

Abstract

A wave of terminations of development programmes for cannabinoid receptor 1 blockers for obesity indicates the demise of a drug class that was once anticipated to yield blockbusters. Nevertheless, lessons learned might help salvage something for future such approaches.

Publication types

  • News

MeSH terms

  • Anti-Obesity Agents / pharmacology
  • Anti-Obesity Agents / therapeutic use*
  • Cannabinoid Receptor Modulators / adverse effects
  • Cannabinoid Receptor Modulators / therapeutic use
  • Dexfenfluramine / adverse effects
  • Dexfenfluramine / therapeutic use
  • Eating / drug effects
  • Humans
  • Life Style
  • Obesity / drug therapy*
  • Obesity / physiopathology
  • Obesity / psychology
  • Piperidines / adverse effects
  • Piperidines / therapeutic use
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use
  • Receptor, Cannabinoid, CB1 / antagonists & inhibitors
  • Receptor, Cannabinoid, CB1 / drug effects*
  • Receptor, Cannabinoid, CB2 / antagonists & inhibitors
  • Receptor, Cannabinoid, CB2 / drug effects
  • Rimonabant
  • Risk Assessment
  • Risk Factors

Substances

  • Anti-Obesity Agents
  • Cannabinoid Receptor Modulators
  • Piperidines
  • Pyrazoles
  • Receptor, Cannabinoid, CB1
  • Receptor, Cannabinoid, CB2
  • Dexfenfluramine
  • Rimonabant